MyFinsight
Home
Blog
About
Contact
Download
Download image
US
$15,202M
(-64.67%↓ Y/Y)
Non Us
$2,360M
US
$5,940M
(-86.20%↓ Y/Y)
Non Us
$2,364M
US
$3,062M
(-92.88%↓ Y/Y)
Non Us
$1,478M
US
$3,151M
(-92.68%↓ Y/Y)
Non Us
$618M
US
$3,612M
(-91.61%↓ Y/Y)
Non Us
$9M
US
$2,048M
(-95.24%↓ Y/Y)
Collaboration revenues-Non Us
$821M
Non Us
$1,486M
US
$1,306M
(-96.96%↓ Y/Y)
US
$1,504M
(-96.50%↓ Y/Y)
Non Us
$1,098M
Non Us
$682M
US
$635M
(-98.52%↓ Y/Y)
US
$1,239M
(-97.12%↓ Y/Y)
Non Us
$32M
US
$1,101M
(-97.44%↓ Y/Y)
Non Us
$164M
US
$906M
(-97.89%↓ Y/Y)
Non Us
$130M
US
$588M
(-98.63%↓ Y/Y)
Non Us
$421M
Non Us
$608M
US
$385M
(-99.11%↓ Y/Y)
US
$864M
(-97.99%↓ Y/Y)
Non Us
$43M
US
$607M
(-98.59%↓ Y/Y)
Non Us
$83M
Non Us
$369M
US
$124M
(-99.71%↓ Y/Y)
Non Us
$315M
US
$167M
(-99.61%↓ Y/Y)
Non Us
$221M
US
$189M
(-99.56%↓ Y/Y)
Non Us
$308M
US
$73M
(-99.83%↓ Y/Y)
Collaboration revenues
$181M
Revenue From Contract
With Customer...
$90M
US
$192M
(-99.55%↓ Y/Y)
Non Us
$15M
Non Us
$144M
US
$53M
(-99.88%↓ Y/Y)
Immunology-SKYRIZI
$17,562M
Immunology-RINVOQ
$8,304M
HUMIRA-Immunology
$4,540M
Botox
Therapeutic-Neuroscience
$3,769M
Neuroscience-Vraylar
$3,621M
Imbruvica-Oncology
$2,869M
Oncology-VENCLEXTA
$2,792M
Other Products
$2,627M
Aesthetics-Botox Cosmetic
$2,602M
Creon-Other Key Products-US
$1,512M
MAVYRET-Other Key Products
$1,317M
Neuroscience-Ubrelvy
$1,271M
Aesthetics-Other Aesthetics
$1,265M
Neuroscience-Qulipta
$1,036M
Eye Care-Other Eye
Care
$1,009M
Aesthetics-Juvederm Collection
$993M
Linzess
Constella-Other Key Products
$907M
Elahere-Oncology
$690M
Eye Care-Ozurdex
$493M
Neuroscience-Vyalev
$482M
Eye Care-Lumigan
Ganfort
$410M
Duodopa-Neuroscience
$381M
Epkinly-Oncology
$271M
Neuroscience-Other Neuroscience
$207M
Alphagan Combigan-Eye
Care
$197M
Oncology-Other Oncology-US
$33M
Net revenues
$61,160M
(8.57%↑ Y/Y)
Operating earnings
$15,075M
(64.99%↑ Y/Y)
Total operating costs
and expenses
$46,085M
(-2.36%↓ Y/Y)
Other operating
income
$241M
(3342.86%↑ Y/Y)
Earnings before income
tax expense
$6,597M
(77.53%↑ Y/Y)
Other expense, net
-$5,793M
(-78.80%↓ Y/Y)
Interest expense, net
-$2,627M
(-21.62%↓ Y/Y)
Net foreign
exchange loss
-$58M
(-176.19%↓ Y/Y)
Cost of products sold
$18,204M
(7.69%↑ Y/Y)
Selling, general and
administrative
$14,010M
(-5.03%↓ Y/Y)
Research and development
$9,096M
(-28.89%↓ Y/Y)
Acquired ipr&d and
milestones
$5,016M
(81.94%↑ Y/Y)
Net earnings
$4,233M
(-1.24%↓ Y/Y)
Income tax expense
(benefit)
$2,364M
(514.74%↑ Y/Y)
Net earnings
attributable to abbvie inc
$4,226M
(-1.22%↓ Y/Y)
Net earnings
attributable to...
$7M
(-12.50%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
ABBV_BIG copy-svg
AbbVie Inc. (ABBV)
ABBV_BIG copy-svg
AbbVie Inc. (ABBV)